Results 71 to 80 of about 83,381 (315)

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]

, 2000
Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston, Derom, Eric, Petrovic, Mirko   +2 more
core  

Disclosure of Maternal HIV Status to Children: To Tell or Not To Tell . . . That Is the Question [PDF]

, 2007
HIV-infected mothers face the challenging decision of whether to disclose their serostatus to their children. From the perspective of both mother and child, we explored the process of disclosure, providing descriptive information and examining the ...
A. Shaffer, B. J. Antle, B. Rime, B. W. C. Forsyth, C. Finkenauer, C. Finkenauer, C. Nostlinger, C. S. Edelbrock, D. A. Murphy, D. A. Murphy, D. A. Murphy, D. A. Murphy, D. A. Murphy, D. J. Pilowsky, D. Melvin, E. W. Schrimshaw, G. E. Wyatt, J. Faithfull, J. M. Simoni, J. Ware, K. E. Grant, K. J. Petrie, L. Armistead, L. Armistead, L. Armistead, L. Armistead, L. J. Bauman, L. Moneyham, L. S. Radloff, L. S. Wiener, M. J. Rotheram-Borus, M. L. Lee, M. Lipson, P. Lester, R. A. Ostrom, R. L. Sowell, R. N. Jamison, S. Dorsey, S. Esposito, S. F. Nagler, S. Harter, T. L. Tompkins, T. M. Achenbach, T. M. Achenbach, T. M. Achenbach, Tanya L. Tompkins, V. N. Niebuhr   +46 more
core   +3 more sources

A novel knee implant for total knee arthroplasty meets expectations at 10 years. First long‐term follow‐up report of clinical outcomes and survivorship

Knee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose Achieving a “forgotten knee” after total knee arthroplasty (TKA) remains a primary goal in modern knee replacement surgery. Anatomic implant designs aim to replicate native knee anatomy and kinematics, potentially improving patient satisfaction and functional outcomes.
Alice Montagna, Marina Marescalchi, Virginia Cinelli, Rudy Sangaletti, Luca Andriollo, Francesco Benazzo, Stefano Marco Paolo Rossi   +6 more
wiley   +1 more source

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries

TH Open, 2019
Introduction Optimizing hemophilia care remains challenging in developing countries. Burden-of-disease studies are important to develop strategies for improving hemophilia care.
Naresh Gupta, Abderrahmane Benbouzid, Meriem Belhani, Mohammed El Andaloussi, Khadija Maani, Yasser Wali, Soraya Benchikh El Fegoun, Hossam Ali Saad, Johnny Mahlangu   +8 more
doaj   +1 more source

Novel variant in HPS3 gene in a patient with Hermansky Pudlak syndrome (HPS) type 3

Platelets, 2020
Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder caused by defects in 10 human HPS genes, characterized by oculocutaneous albinism (OCA) and bleeding diathesis associated to platelet δ-storage pool defect (SPD).
Anna Lecchi, Silvia La Marca, Eti A Femia, Antonia Lenz, Doris Boeckelmann, Andrea Artoni, Flora Peyvandi, Barbara Zieger   +7 more
doaj   +1 more source

Antithrombin: Deficiency, Diversity, and the Future of Diagnostics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Our healthcare system provides reactive sick‐care, treating patients after symptoms have appeared by prescription of generic and often suboptimal therapy. This strategy brings along high costs and high pressure which is not sustainable.
Mirjam Kruijt, Christa M. Cobbaert, L. Renee Ruhaak   +2 more
wiley   +1 more source

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

Research and Practice in Thrombosis and Haemostasis, 2020
Background Hemophilia gene therapy is a rapidly evolving therapeutic approach in which a number of programs are approaching clinical development completion.
Flora Peyvandi, David Lillicrap, Johnny Mahlangu, Claire McLintock, K. John Pasi, Steven W. Pipe, Wendy Scales, Alok Srivastava, Thierry VandenDriessche   +8 more
doaj   +1 more source

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. [PDF]

, 2008
BackgroundActivated factor X (FXa) is a vitamin K-dependent serine protease that plays a pivotal role in blood coagulation by converting prothrombin to thrombin. There are no reports of humans with complete deficiency of FX, and knockout of murine F10 is
Arruda, VR, Chu, K, Golden, JA, Herzog, RW, High, KA, Labosky, PA, Margaritis, P, Tai, SJ   +7 more
core   +2 more sources

Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Hemophilia A (HA) is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Prophylactic FVIII replacement therapy is essential for preventing bleeds, but it carries a risk of inhibitor development, especially in previously untreated and minimally treated patients (PUPs and MTPs, respectively).
Sarina Levy‐Mendelovich, Tlalit Barhod, Ivan Budnik, Jonathan Lancashire, Jesal Patel, Assaf Arie Barg, Einat Avishai, Rima Dardik, Tami Brutman Barazani, Tami Livnat, Jayashree Motwani, Gili Kenet   +11 more
wiley   +1 more source

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source